BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24586741)

  • 1. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
    Jardim DL; Wheler JJ; Hess K; Tsimberidou AM; Zinner R; Janku F; Subbiah V; Naing A; Piha-Paul SA; Westin SN; Roy-Chowdhuri S; Meric-Bernstam F; Hong DS
    PLoS One; 2014; 9(2):e89388. PubMed ID: 24586741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.
    Mao JH; Kim IJ; Wu D; Climent J; Kang HC; DelRosario R; Balmain A
    Science; 2008 Sep; 321(5895):1499-502. PubMed ID: 18787170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling reveals transcriptional regulation by Fbxw7/mTOR pathway in radiation-induced mouse thymic lymphomas.
    Snijders AM; Liu Y; Su L; Huang Y; Mao JH
    Oncotarget; 2015 Dec; 6(42):44794-805. PubMed ID: 26575021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
    Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
    Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
    Mansour MR; Sulis ML; Duke V; Foroni L; Jenkinson S; Koo K; Allen CG; Gale RE; Buck G; Richards S; Paietta E; Rowe JM; Tallman MS; Goldstone AH; Ferrando AA; Linch DC
    J Clin Oncol; 2009 Sep; 27(26):4352-6. PubMed ID: 19635999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.
    Chang CC; Lin HH; Lin JK; Lin CC; Lan YT; Wang HS; Yang SH; Chen WS; Lin TC; Jiang JK; Chang SC
    Int J Biol Markers; 2015 Feb; 30(1):e88-95. PubMed ID: 25450649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development.
    Liu Y; Huang Y; Wang Z; Huang Y; Li X; Louie A; Wei G; Mao JH
    Aging (Albany NY); 2013 Feb; 5(2):111-9. PubMed ID: 23454868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
    Asnafi V; Buzyn A; Le Noir S; Baleydier F; Simon A; Beldjord K; Reman O; Witz F; Fagot T; Tavernier E; Turlure P; Leguay T; Huguet F; Vernant JP; Daniel F; Béné MC; Ifrah N; Thomas X; Dombret H; Macintyre E
    Blood; 2009 Apr; 113(17):3918-24. PubMed ID: 19109228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple novel alternative splicing forms of FBXW7α have a translational modulatory function and show specific alteration in human cancer.
    Liu Y; Ren S; Castellanos-Martin A; Perez-Losada J; Kwon YW; Huang Y; Wang Z; Abad M; Cruz-Hernandez JJ; Rodriguez CA; Sun Y; Mao JH
    PLoS One; 2012; 7(11):e49453. PubMed ID: 23166673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.
    Wang Y; Liu Y; Lu J; Zhang P; Wang Y; Xu Y; Wang Z; Mao JH; Wei G
    Biochem Biophys Res Commun; 2013 May; 434(2):352-6. PubMed ID: 23558291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines.
    Davis H; Lewis A; Behrens A; Tomlinson I
    Gut; 2014 May; 63(5):792-9. PubMed ID: 23676439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fbxw7 Limits Myelination by Inhibiting mTOR Signaling.
    Kearns CA; Ravanelli AM; Cooper K; Appel B
    J Neurosci; 2015 Nov; 35(44):14861-71. PubMed ID: 26538655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDC4/FBXW7 and the 'just enough' model of tumourigenesis.
    Davis H; Tomlinson I
    J Pathol; 2012 Jun; 227(2):131-5. PubMed ID: 22323043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
    Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
    Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
    Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
    Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
    Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
    Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.
    Calcagno DQ; Freitas VM; Leal MF; de Souza CR; Demachki S; Montenegro R; Assumpção PP; Khayat AS; Smith Mde A; dos Santos AK; Burbano RR
    BMC Gastroenterol; 2013 Sep; 13():141. PubMed ID: 24053468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FBXW7 mutations in melanoma and a new therapeutic paradigm.
    Aydin IT; Melamed RD; Adams SJ; Castillo-Martin M; Demir A; Bryk D; Brunner G; Cordon-Cardo C; Osman I; Rabadan R; Celebi JT
    J Natl Cancer Inst; 2014 Jun; 106(6):dju107. PubMed ID: 24838835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
    Baldus CD; Thibaut J; Goekbuget N; Stroux A; Schlee C; Mossner M; Burmeister T; Schwartz S; Bloomfield CD; Hoelzer D; Thiel E; Hofmann WK
    Haematologica; 2009 Oct; 94(10):1383-90. PubMed ID: 19794083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.